tldrdaily.news logo
Tag

Prostate Cancer

All articles tagged with #prostate cancer

Tiny Plastics Detected in 9 of 10 Prostate Tumors, NYU Study Finds
health1 day ago

Tiny Plastics Detected in 9 of 10 Prostate Tumors, NYU Study Finds

A pilot NYU Langone Health study found microplastic particles in 9 of 10 prostate tumor samples, with cancerous tissue averaging about 40 micrograms per gram versus 16 in healthy tissue (roughly 2.5x higher). The team took rigorous contamination precautions, including using nonplastic tools, and analyzed 12 common plastic molecules. While findings raise the possibility that microplastics could influence cancer risk via inflammation, researchers caution that the small sample size requires larger studies to confirm any causal role; results will be presented at the ASCO Genitourinary Cancers Symposium.

via SciTechDaily|
#cancer-research#health#inflammation
Astellas and Vir Strike Global Deal to Advance VIR-5500 for Prostate Cancer
business1 day ago

Astellas and Vir Strike Global Deal to Advance VIR-5500 for Prostate Cancer

Astellas and Vir Biotechnology announced a global strategic collaboration to co-develop and co-commercialize VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager for prostate cancer; U.S. commercialization led by Astellas (Vir may co-promote), ex-U.S. commercialization to Astellas, development costs shared 60/40 (Astellas/Vir), Vir to receive $335 million upfront/near-term payments and up to $1.37 billion in milestones, with royalties on ex-U.S. net sales and a potential 50/50 U.S. profit/loss share if Vir elects to co-promote; closing subject to customary regulatory clearances.

via Vir Biotechnology|
#astellas#business#prostate-cancer
Astellas inks $1.7B collaboration to push Vir’s PSMA-targeted T-cell engager
business2 days ago

Astellas inks $1.7B collaboration to push Vir’s PSMA-targeted T-cell engager

Astellas is partnering with Vir Biotechnology in a $1.7 billion deal to advance VIR-5500, Vir’s PSMAxCD3 T-cell engager, leveraging Vir’s PRO-XTEN dual-masking tech; Astellas pays $335 million upfront (cash, equity, milestones) with potential up to $1.37 billion in milestones, and a 60-40 development-cost split, plus a U.S. co-promotion option and non-U.S. commercialization by Astellas. The alliance aims for phase 3 in 2027 with expanded early-lines; ASCO GU data show encouraging PSA reductions and a 45% objective response rate in evaluable patients, with a manageable safety profile (mostly grade 1 CRS) at the go-forward dose.

via Fierce Biotech|
#business#clinical-trials#immuno-oncology
Tiny plastics found inside prostate tumors spark research questions
health2 days ago

Tiny plastics found inside prostate tumors spark research questions

In a small, not-yet-peer-reviewed study of 10 men with prostate cancer, researchers found microplastics in 90% of tumor samples and 70% of nearby noncancerous tissue, with higher concentrations in tumors. The findings are preliminary, the study took extensive contamination precautions, and larger studies are needed to determine any causal link or health implications.

via NBC News|
#contamination#health#microplastics
UK prostate cancer patients denied life-preserving focal therapy
healthcare2 days ago

UK prostate cancer patients denied life-preserving focal therapy

Thousands of UK men with prostate cancer are reportedly being denied focal therapy, a non-invasive treatment that preserves quality of life by reducing side effects like erectile dysfunction and incontinence; despite three principal forms (HIFU, cryotherapy, NanoKnife) being available, the NHS offers access at only a few centres and doctors say patients aren’t routinely informed about this option, prompting calls for broader access amid supportive trial data and NICE approvals.

via The Times|
#focal-therapy#healthcare#nhs
Dietary Fat Shifts in Cooking Oils May Slow Prostate Cancer Growth, Small Study Suggests
lifestyle11 days ago

Dietary Fat Shifts in Cooking Oils May Slow Prostate Cancer Growth, Small Study Suggests

A small UCLA-led trial in men with early prostate cancer on active surveillance found that reducing omega-6 fats and increasing omega-3 fats (via diet and fish oil) correlated with slower cancer cell growth, evidenced by lower Ki-67 after one year; PSA and tumor grade didn’t change. The study isn’t proof and larger, longer research is needed, but practical steps include cutting fried/ultra-processed foods and eating fatty fish regularly.

via Earth.com|
#cooking-oils#ki-67#lifestyle
Early Signals: Subtle Prostate Cancer Symptoms Men 40+ Should Not Ignore
health20 days ago

Early Signals: Subtle Prostate Cancer Symptoms Men 40+ Should Not Ignore

Medical professionals warn that men over 40 should watch for early prostate cancer signs, including more frequent urination (especially at night), difficulty starting or stopping urine flow, a sense that the bladder won’t fully empty, blood in urine or semen, new erectile issues or painful ejaculation, persistent lower-back/hip/pelvic pain, and unexplained fatigue or weight loss. If symptoms persist for weeks, consult a GP promptly for assessment and potential PSA testing, with Prostate Cancer UK providing resources and support.

via Men's Health|
#early-detection#health#mens-health
Preparing for the End: A Model for Dying With Dignity
health22 days ago

Preparing for the End: A Model for Dying With Dignity

NYT profile of Brian Cahill, a 58-year-old with metastatic prostate cancer who reorganizes his life around care, planning, and relationships. He builds a supportive circle for medical decisions, relocates from NYC to Cincinnati for affordable hospice care, and even considers a temporary drug holiday to regain energy and autonomy. The piece frames a “good death” as one shaped by preparation, connection, and living fully within limited time, using his experiences as a blueprint for dying with dignity.

via The New York Times|
#caregiving#end-of-life#health
health-and-wellness1 month ago

Two-dose radiation could redefine prostate cancer treatment

A Rabin Medical Center study suggests prostate cancer patients could be treated with only two radiation doses instead of five, potentially changing the global standard of care. The ongoing trial of over 100 participants aims to preserve effectiveness and avoid increased side effects through highly focused, personalized radiotherapy, with early patient improvements reported amid Israel's relatively high incidence of prostate cancer.

via jpost.com|
#clinical-study#health-and-wellness#prostate-cancer
UK Prostate Cancer Now Most-Diagnosed Cancer, Spotlighting Screening Gaps and Inequities
health1 month ago

UK Prostate Cancer Now Most-Diagnosed Cancer, Spotlighting Screening Gaps and Inequities

A UK-wide analysis finds prostate cancer is now the most commonly diagnosed cancer, with 64,425 cases in 2022 (surpassing 61,640 breast cancers). The data reveal regional and demographic disparities: more late-stage diagnoses in Scotland, higher risk for black men, and a 29% greater likelihood of metastatic cancer in deprived areas, alongside ongoing debates over PSA screening and calls for targeted early-detection programs; the lifetime risk is about 1 in 8 men, with roughly 12,200 deaths annually.

via The Guardian|
#health#health-disparities#late-stage-diagnosis
Dilbert Creator Scott Adams Dies at 68 Amid Racism Fallout
entertainment1 month ago

Dilbert Creator Scott Adams Dies at 68 Amid Racism Fallout

Scott Adams, the cartoonist behind Dilbert, died at 68 from prostate cancer. He built the strip into a major late-20th-century brand with bestselling books and a 1999–2000 Dilbert animated series on UPN, but his career collapsed after racist remarks in 2023 led newspapers and distributors to drop the strip, ending his mainstream influence in comics and animation.

via Cartoon Brew|
#dilbert#entertainment#prostate-cancer
health1 month ago

Croatia rolls out nationwide PSA screening as the UK weighs its approach

Croatia has announced a national prostate cancer screening programme offering annual PSA tests for men aged 55–69, set to begin next year, as the UK debates its own stance after the UK National Screening Committee’s cautious recommendation; early data show Croatia’s five-year survival is higher than Britain's, with several other countries piloting or planning routine PSA screenings.

via The Telegraph|
#croatia#health#prostate-cancer